GW Pharmaceuticals PLC- Sees Large Growth in Short Interest (GWPH)
GW Pharmaceuticals PLC- (NASDAQ:GWPH) was the target of a significant growth in short interest during the month of April. As of April 30th, there was short interest totalling 1,682,871 shares, a growth of 228.4% from the April 15th total of 512,379 shares, AnalystRatingsNetwork reports. Based on an average trading volume of 2,412,574 shares, the days-to-cover ratio is presently 0.7 days. Approximately 9.4% of the shares of the stock are sold short.
A number of research firms have recently commented on GWPH. Analysts at Morgan Stanley reiterated an “overweight” rating on shares of GW Pharmaceuticals PLC- in a research note on Friday. They now have a $103.00 price target on the stock. Separately, analysts at Leerink Swann raised their price target on shares of GW Pharmaceuticals PLC- from $79.00 to $90.00 in a research note on Thursday, May 8th. They now have an “outperform” rating on the stock. Finally, analysts at Canaccord Genuity raised their price target on shares of GW Pharmaceuticals PLC- from $65.00 to $102.00 in a research note on Thursday, May 8th. They now have a “buy” rating on the stock. Eight analysts have rated the stock with a buy rating, The stock presently has an average rating of “Buy” and a consensus target price of $66.50.
GW Pharmaceuticals PLC- (NASDAQ:GWPH) opened at 68.31 on Monday. GW Pharmaceuticals PLC- has a 1-year low of $8.46 and a 1-year high of $86.45. The stock’s 50-day moving average is $61.44 and its 200-day moving average is $51.7. The company’s market cap is $1.193 billion.
GW Pharmaceuticals PLC- (NASDAQ:GWPH) last issued its quarterly earnings data on Wednesday, May 7th. The company reported ($0.04) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.48) by $0.44. The company had revenue of $12.55 million for the quarter, compared to the consensus estimate of $12.48 million. The company’s quarterly revenue was up 63.6% on a year-over-year basis. Analysts expect that GW Pharmaceuticals PLC- will post $-1.85 EPS for the current fiscal year.
GW Pharmaceuticals plc is a United Kingdom-based company. The Company is engaged in the research, development and commercialization of a range of cannabinoid prescription medicines to meet patient needs in a range of medical conditions.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.